Enalapril

• Description :

  Enalapril (MK-421) is an angiotensin-converting enzyme (ACE) inhibitor, can be used for hypertensive diseases research[1][2].

• Product Name Alternative :

  MK-421

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Angiotensin-converting Enzyme (ACE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/enalapril.html

• Purity :

  99.96

• Solubility :

  DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

• Smiles :

  O=C(O)[C@H]1N(C([C@H](C)N[C@H](C(OCC)=O)CCC2=CC=CC=C2)=O)CCC1

• Molecular Formula :

  C20H28N2O5

• Molecular Weight :

  376.45

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Serge Sicouri, et al. Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol. 2011 Jun;22 (6) :698-705.|[2]Rokhsareh Meamar, et al. Enalapril protects endothelial cells against induced apoptosis in Alzheimer's disease. J Res Med Sci. 2013 Mar;18 (Suppl 1) :S1-5.|[3]Talita A Cunha, et al. Effect of stearic acid on enalapril stability and dissolution from multiparticulate solid dosage forms. AAPS PharmSciTech. 2013 Sep;14 (3) :1150-7.|[4]A Ravati, et al. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol. 1999 May 28;373 (1) :21-33.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Citation 01 :

  Am J Transl Res. 2022 Jan 15;14 (1) :211-222.|Elife. 2025 Aug 28:14:RP104774.|Int J Clin Exp Pathol. 2020 May 1;13 (5) :827-836.|Nat Commun. 2023 May 2;14 (1) :2523.|Ren Fail. 2023;45 (2) :2253924.|bioRxiv. 2024 November 28.|bioRxiv. 2025 Jun 27:2025.06.24.660441.|Cardiooncology. 2025 Nov 13;11 (1) :106.|Environ Pollut. 2019 Apr:247:927-934.|Int J Nanomedicine. 2025 Oct 27:20:12993-13006.|Toxicol Lett. 2019 Jul:309:42-50.|Toxicology. 2023 Mar 1:486:153442.

• CAS Number :

  [75847-73-3]